Nicotinamide adenine dinucleotide oxidases (NOXs) are important contributors to cellular oxidative stress in the cardiovascular system. The NOX2 isoform is upregulated in numerous disorders, including dystrophic cardiomyopathy, where it drives the progression of the disease. However, mechanisms underlying NOX2 overexpression are still unknown. We investigated the role of microRNAs (miRs) in the regulation of NOX2 expression.
Introduction
Oxidative stress is implicated in the development of numerous cardiovascular pathologies, such as cardiac hypertrophy (CH), heart failure (HF), myocardial infarction (MI), hypertension, atherosclerosis, and stroke (reviewed in 1 -3 ). It is a result of excessive generation of reactive oxygen species (ROS) as well as of reduced antioxidant capacity in the vasculature and heart. ROS are produced by most of cardiovascular cell types, including endothelial and smooth muscle cells as well as cardiomyocytes. They are generated by various sources: enzymes, such as xanthine oxidize and nicotinamide adenine dinucleotide oxidase (NOX), and mitochondria. It is currently believed that ROS action highly depends on their source, cellular location, and type of species that are generated. Among different sources of ROS, the NOX family of enzymes is particularly important for redox signalling in the physiology and pathophysiology of the heart. NOX2 and NOX4 are two major isoforms expressed in cardiac tissue. 4 Increased levels of NOX2 and/or its activity have been shown to be involved in ROS-dependent hypertrophic cardiac responses, myocardial inflammation and fibrosis, post-MI remodelling as well as in initiating and maintaining atrial fibrillation. 2 Recent studies demonstrated that NOX2-driven oxidative stress is involved in the pathology of Duchenne muscular dystrophy (DMD). 4, 5 DMD is a fatal rapidly developing muscle wasting disease caused by an X-linked mutation in the dystrophin gene. Cardiac complications of the disease develop in the majority of boys with DMD. About 20% (and increasing) of adolescent patients develop ventricular dysfunctions and arrhythmias that ultimately lead to HF. 2, 6, 7 The cellular pathophysiology of the heart of mdx mouse (an animal model of DMD) includes oxidative stress and impaired Ca 2+ signalling. 8 -16 These pathophysiological features are observed at very early stages of the disease, well before the first sign of cardiomyopathy is apparent. 17 Our recent report suggests that oxidation of the intracellular environment initiates post-translational modifications of Ca 2+ release channels (ryanodine receptors, RyR) in sarcoplasmic reticulum (SR) leading to the increased sensitivity of RyR to activation by Ca 2+ . 17 The latter results in intensified Ca 2+ signalling, activation of apoptotic and necrotic pathways and consequently, the loss-of-functional myocytes and development of fibrosis. 5 The major source of oxidative stress in young mdx hearts is NOX2. NOX2 expression and NOX2-derived ROS production is significantly increased in dystrophy, and this clearly precedes the first clinical manifestation of dystrophic cardiomyopathy. 11, 17 Therefore, oxidative stress and NOX2 are considered to be appealing targets in developing new therapies for muscular dystrophy as well as for some other cardiac diseases mentioned above.
As of today, overall outcomes of clinical studies investigating effects of antioxidants have been disappointing, despite the promising results of the same experiments with research animals. Therefore, the employment of new approaches is a necessary and important step in a therapeutic design. One of the possibilities is to regulate the expression of the gene of interest. microRNAs (miRs) is a group of endogenous, short non-coding RNAs. 18 These molecules play a critical role in translational and posttranscriptional regulation of gene expression. They finely tune the output of target messenger RNAs (mRNAs) by their destabilization and/or translational inhibition. 19 A number of miRs are primarily expressed in skeletal and cardiac muscles (miR-1, miR-21, miR-133, miR-208, etc.). These housekeeping molecules play important roles in muscle development, regeneration, myogenesis, electrical remodelling, progression of fibrosis, etc. 20, 21 Other miRs are expressed in other tissues, but can still affect distant targets, including muscle, by circulating in the blood stream. 22 There are limited reports on the role of miRs in muscle dystrophy. They are either related to the skeletal muscle phenotype of the disease or restricted to the characterization of the miRs expression profile. 23, 24 To the best of our knowledge, no studies linking oxidative stress in dystrophy to the dysregulation of miRs were reported. Moreover, there is very little known about regulation of NOX2 expression by miRs. The aim of this study was to identify miR(s) that regulate NOX2 expression in cardiac dystrophy at preclinical stages of the disease. In addition, we wanted to determine if experimental manipulation of these miR(s) in control wild-type (WT) mice induces a dystrophic cardiac phenotype and leads to the deterioration of cardiac function at the molecular, cellular, and organ levels. NOX2 contains a membrane-bound core, comprising a catalytic gp91 phox subunit and a p22 phox subunit, as well as four regulatory subunits: p67 phox , p40 phox , p47 phox , and Rac1. 2, 4 The regulatory subunits must translocate from the cytosol to the membrane to form an active enzyme. We found a 10-fold downregulation of miR-448-3p in hearts of young dystrophic mice. The latter correlated with overexpression of the Ncf1 gene, encoding the NOX2 regulatory subunit p47 phox . Acute inhibition of miR-448-3p in WT mice with LNA-miR-448-3p inhibitors resulted in an increase in Ncf1 expression as well as in enhanced ROS production and exacerbated intracellular Ca 2+ signalling in isolated cardiomyocytes. In addition, chronic (over 1 month) inhibition of miR-448 led to the deterioration of cardiac contractility and development of arrhythmia. Our data suggest that downregulation of miR-448-3p relieves inhibition of Ncf1 translation in dystrophic cardiomyopathy. It results in an increase in Ncf1 expression and consequently in oxidative stress and enhanced Ca 2+ signalling in dystrophic heart, cellular events underlying muscle damage. The results of our studies can also be applied to many other cardiac diseases associated with NOX2-derived ROS-driven oxidative stress. Overall, our data point to miR-448-3p as a potential therapeutic target in various cardiac pathologies.
Materials and methods
All experiments conformed to the NIH Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH publication, 8th edition, 2011) and were approved by the Institutional Animal Care and Use Committee of the New Jersey Medical School, Rutgers University, USA. Brief protocol descriptions are below, and all methods are described in details in Supplementary material online.
Cell isolation
C57BL10 mice (WT) and dystrophin-deficient mdx (C57BL/10ScSnmdx) mice at the age of 1 month (young), 3 -4 months (adults), and at least 15 months old (senescent) were used in this study. Animals were purchased from the Jackson Laboratory. Ventricular myocytes from mouse heart were isolated as previously described. 25 
RNA purification and real-time reverse transcription PCR
Total RNA was isolated using Tri-Reagent w and Direct-zol RNA MiniPrep (Zymo Research, Irvine, CA, USA) and quantified using Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Real-time PCR was performed using 7500 Fast Real-Time PCR system (Applied Biosystems) and different detection assays.
Western blots
Protein extractions and western blotting were performed as previously described. 17 
Luciferase reporter assay
HEK293 cells were seeded in 96-well plates. Ncf1 3 ′ -UTR, mutated Ncf1 3 ′ -UTR, or control luciferase reporter plasmid (GeneCopoeia) was cotransfected with either mirVana TM miR mimic hsa-miR-448 or mirVanaTM miR mimic negative control (NC; Ambion) using FugeneHD:DNA ratio of 3:1 (Promega), or Lipofectamine 3000 (Thermofisher, MA, USA). Luciferase activity was measured with Secre-Pair TM Dual-Luciferase
Reporter Assay (GeneCopoeia).
LNA-antimiR inhibitors
The miRCURY LNA TM miR inhibitors were purchased from Exiqon (Exiqon, Woburn, MA, USA) and used as described in Supplementary material online.
Confocal imaging
Changes in cytoplasmic [Ca 2+ ] and ROS production were monitored with fluorescent indicators fluo-4 AM and CM-H 2 DCFDA, respectively.
Histological analysis
Histological analysis was performed on heart samples fixed in 10% buffered formalin and embedded in paraffin as described in Supplementary material online.
miR-448-ROS-induced cardiomyopathy
Cytokine assays
Proteome profiler mouse cytokine array panel A (R&D systems, MN, USA, cat #ARY006) was used to measure the levels of selective chemokine and cytokines in samples.
Echocardiography
Echocardiography was performed on avertin (2.5% tribromethanol) anaesthetized mice (290 mg/kg, IP) with Acuson Sequoia C256 Ultrasound System.
Data analysis and statistics
Results are shown as mean + standard error of mean, unless otherwise specified. All biochemical and functional data sets contain results from 3 to 6 mice. Cellular studies were carried out on cells isolated from at least three mice. The variable N indicates the number of animals used, and n specifies the number of cells studied. Pairwise comparisons between two groups were made by unpaired two-tailed Student's t-test. P-value of ,0.05 and less was considered to be significant. Statistical analyses were performed with the Sigma Plot 13 software (Systat Software Inc., San Jose, CA, USA). Image processing and analyses were done with ImageJ software (public domain software developed by NIH).
Results

Overexpression of NOX2 is associated with oxidative stress in dystrophic heart
We have already demonstrated that NOX2-derived ROS production is enhanced in dystrophic heart well before cardiac myopathy is detected. 17 In particular, using fluorescence ROS-sensitive indicator CM-H 2 DCFDA, we have shown that the extent of ROS production in ventricular cardiomyocytes isolated from young (1 month old) mdx animals is significantly greater than in cells from WT hearts.
6,17
The slope of change in DCF fluorescence (the fluorescent derivative of CM-H 2 DCFDA) detected with confocal imaging reflects the rate of ROS production. In agreement with our previous report, Figure 1A shows that the slope was significantly greater in mdx myocytes compared with that in WT cells. Here we also demonstrate that this difference is completely eliminated by the DPI (diphenylene iodonium, 10 mM), inhibitor of membrane-bound gp91 phox subunit of NOX2 complex. Please note that ROS generation in mdx myocytes after incubation with DPI was reduced to levels even lower than that of WT cells. This suggests that NOX2 is not only the major contributor to oxidative stress in young dystrophic hearts but it also contributes to cytosolic redox potential in WT cells. In addition, we previously reported a similar reduction in ROS production by apocynin, 10,17 a drug which has different pharmacological mechanism of action. Apocynin inhibits translocation of the regulatory p47 phox subunit of NOX2 to the membrane.
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Next, we quantified mRNA levels of genes encoding all six subunits of NOX2 with qPCR. Cybb gene encoding gp91 phox subunit, as well as
Rac1 genes in young (1 month old), adult (3-4 months old), and senescent (15 -16 months old) both in WT and mdx cardiac tissue were tested ( Figure 1B ). We found that mRNA expression of Cybb and Ncf1 genes significantly increased in mdx cardiac tissue starting from early age (1 month old), whereas levels of Cyba, Ncf2, Ncf4, and Rac1 mRNA were essentially unchanged. In addition, western blot analysis showed that gp91 phox and regulatory p47 phox subunits proteins are overexpressed in hearts of young mdx mice compared with WT ( Figure 1C ).
Upregulation of Ncf1 gene in heart tissue is mediated by miR-448
Initial screening of miR using the mouse miRNome Sanger miRBase miR Profiler Set (System Bioscience, CA, USA) revealed significant changes in miR expression in hearts of mdx mice of different ages compared with WT. In young hearts, for example, 65% of miRs were downregulated, 4% were upregulated, and 31% did not change (Supplementary material online, Figure S1 ). Based on this screening and results of miR target prediction databases (miRWalk, miRBase, TargetScan, and miRanda), we selected 12 miRs with predicted targeting of Cybb (miR-9, miR-92, miR-224, miR-17, and miR-138) and Ncf1 (miR-17, miR-138, and miR-448) in addition to miRs shown to be associated with cardiac dysfunctions (miR-1, miR-21, miR-23, miR-29, and miR-320). As expected, some of the cardiacspecific miRs (in particular miR-1 and miR-21) were increased, especially in adult hearts already displaying cardiac myopathy ( Figure 2A) . We have also found that expression of miR-9 and miR-448 in dystrophic heart was significantly and constitutively decreased in all age groups ( Figure 2A and Supplementary material online, Table S1 ), which correlates with an increased expression of their predicted target genes, Cybb and Ncf1, encoding two subunits of NOX2, as seen in Figure 1B . In the present study, we choose to focus on miR-448 and miR-9, as their levels were already significantly reduced in hearts of very young animals that did not yet develop cardiomyopathy but already showing signs of oxidative stress. 8 -17 In rodents (mice and rats) biogenesis of miR-448 results in two mature forms-miR-448-3p and miR-448-5p, which originate from 3 ′ and/or 5 ′ of precursor pre-miR-448 correspondingly. Analysis of qPCR showed dramatic downregulation of both of these forms in dystrophic heart ( Figure 2A) . However, only the mature mouse miR-448-3p, but not miR-448-5p, sequence is highly conserved among all species, including humans, where it is called miR-448. Therefore, miR-448-3p was selected for further investigation.
There are substantial limitations of in silico bioinformatics tools and broad screening techniques. Therefore, we carried out in vitro experiments to confirm that Ncf1 (p47 phox ), as well as Cybb (gp91 phox ) are indeed targets of miR-448-3p and miR-9, respectively. Using luciferase reporter assay, we found that luciferase activity is significantly decreased when HEK-293 cells were co-transfected with a luciferase construct containing mouse 3 ′ UTR region of Ncf1 and mimic or precursor of miR-448-3p, a.k.a.
pre-miR ( Figure 2C and Supplementary material online, Figure S2C ), in comparison with the same experiments when scrambled mimic or precursor was used (a.k.a. NC). Moreover, the inhibition of the luciferase signal was dose dependent (additional test for target specificity, Figure 2C ). In addition, when HEK-293 cells were co-transfected with a luciferase construct containing mutated mouse 3 ′ UTR region of Ncf1 (mutation for miR-448 seed region) and miR-448-3p mimics (yet another crucial test for targeting), no significant changes in the luciferase signal were observed. Identical experiments with a luciferase construct containing mouse 3 ′ UTR region of Cybb were conducted to test if miR-9 targets this gene. No changes in the level of inhibition of luciferase activity were detected with an increased concentration of miR-9 mimic (Supplementary material online, Figure S2B ). Therefore, we selected miR-448 for the rest of the studies, which, as validated by the data above, regulates the expression of Ncf1 gene.
Acute systemic inhibition of miR-448-3p increases Ncf1 expression in WT hearts
Previous studies demonstrated that individual miRs in the heart can be inhibited by anti-miRs-chemically modified antisense oligonucleotides. 29 Among them are LNA-miR inhibitors, based on Locked
Nucleic Acid (LNA TM ) Technology. To determine the role of miR-448-3p in vivo, we injected WT mice with miRCURY LNA TM miR-448-3p inhibitor (Exiqon, Woburn, MA, 10 mg/kg and 25 mg/ kg) or with scrambled LNA-NC (10 mg/kg) through a tail vein according to manufacturer's protocol (Figure 3) . Three days after the last injection, mice were sacrificed and qPCR and western blots were performed on heart tissue. Our results indicate that in vivo inhibition of miR-448-3p with its LNA-antimiR inhibitor significantly increased Ncf1 expression on both, gene ( Figure 3B ) and protein ( Figure 3C ) levels. phox and p47 phox subunits in dystrophic heart compared with WT cardiac tissue, N ¼ 5. *P , 0.05, **P , 0.001, t-test.
Acute systemic inhibition of miR-448-3p induces cellular phenotype of dystrophic hearts
In a parallel group of experiments, we examined intracellular ROS production (with H 2 DCFDA) and intracellular Ca 2+ stretch-response (with Fluo-4) in ventricular cardiomyocytes isolated from WT mice acutely injected either with miRCURY LNA TM miR-448-3p inhibitor (10 or 25 mg/kg) or with its NC (scrambled inhibitor, NC, 10 mg/kg), as described above. As illustrated in Figure 4A , inhibition of miR-448-3p resulted in a significant increase in intracellular ROS production as indicated by the increase in ROS-dependent DCF Figure 2 Changes in miRs expression in dystrophic heart. (A) Real-time PCR analysis of cardio-specific miRs and miRs predicted to target Cybb and Ncf1 genes. Graphs show changes in miR levels in mdx hearts relative to their levels in WT samples (indicated by dashed line). N ¼ 5-6, *P , 0.05, t-test. (B) Genomic localization of mmu-miR-448 on intron 4 of the Htr2C gene located on X-chromosome of mouse genome. It is further processed to pre-miR-448 and later to the mature miR-448, where miR-448-3p is conserved among species. (C) Left, schematic representation of miR-448-3p binding region ('seed region') in mouse Ncf1 gene. On the bottom is the map of quadruple mutant (mutated residuals is in light grey). Right, luciferase activity assay shows the dose-dependent decrease of luciferase activity in cells transfected with miR-448 mimic and NCF1-3 ′ UTR plasmid, but not with construct with the mutated seed region. For each transfection, a total of six wells for each condition were collected and measured individually, and then averaged (n ¼ 6). A total of three separate transfections were assayed and averaged (N ¼ 3). *P , 0.05, t-test.
fluorescence signal. Incubation of myocytes with NOX2 inhibitor DPI decreased ROS level in all treated groups of animals to the same level, implying that increase of basal ROS level in cardiomyocytes after systemic miR-448-3p inhibition is an NOX2-dependent process.
As we previously reported, mechanical stress applied as osmotic shock triggered intensified Ca 2+ signals (sparks and waves) in mdx but not in WT cardiomyocytes. 10, 17 This observation was later confirmed with more physiological longitudinal stress. 16 Recently, we found that the enhancement in Ca 2+ responses to mechanical stress is due to post-translational modifications of RyRs resulting in the increase of their Ca 2+ sensitivity because of oxidation of the intracellular environment. 11, 17 Here we applied the same protocol to evaluate sensitivity of RyRs in ventricular cardiomyocytes obtained from WT mice treated with LNA-miR-448-3p and LNA-NC ( Figure 4B ). Cells were loaded with Fluo-4 AM and then imaged with confocal microscopy during osmotic challenge (protocol is shown on the top of left panel in Figure 4B ). 
Chronic inhibition of miR-448p stimulates cardiac remodelling and cardiomyopathy
To examine the consequences of downregulation of miR-448-3p on cardiac function, we designed experiments aimed to chronically inhibit miR-448-3p in WT mice ( Figure 5A ). For this, we performed three initial injections of 10 mg/kg miRCURY LNA TM miR-448-3p inhibitor or scrambled LNA-NC followed by three single injections with 7 days interval and then evaluated functional and morphological properties of the heart. As in case of acute inhibition, this intervention significantly increased the expression of p47 phox subunit of NOX2 at gene and protein levels ( Figure 5B ). Cardiac function was monitored in sedated mice using ultrasound system. Chronic treatment of WT mice with LNA-miR-448-3p reduced contractile properties of the hearts when compared with hearts of animals treated with LNA-NC. Table S2 ). Some animals treated with LNA-448-3p also exhibited arrhythmia (as shown in Figure 5C , echogram on the bottom left). In addition to functional changes, some morphological and histological alterations of heart tissue were also detected after a prolonged LNA-miR-448-3p regime. Figure 6A depicts hearts of animals treated with either LNA-miR-448-3p or with LNA-NC. Note that LNA-miR-448-3p-treated hearts were already somewhat hypertrophied. The body/heart weight ratio increased from 6.98 + 0. 18  (N ¼ 3) to 7.23 + 0.15 (N ¼ 3) . Besides, echocardiography revealed Table S2 ), suggesting the development of a dilated cardiomyopathy. A significant increase in crosssectional area of ventricular myocytes from LNA-miR-448-3p-treated hearts was also detected ( Figure 6B ). Decrease in cardiac contractility is often associated with development of fibrosis in myocardium. Therefore, we next examined histological properties of the hearts with Masson trichrome and picric acid sirius red. Two hundred and nine sections (N ¼ 3) of right and left ventricles as well as of intersectional septum of hearts removed from animals treated with LNA-miR-448-3p were compared with similar 166 sections (N ¼ 3) of hearts treated with LNA-NC. A significant increase in perivascular fibrosis was detected in hearts exposed to chronic inhibition of miR-448 ( Figure 6C and D) .
Furthermore, we found that multiple mRNAs associated with genes involved in cardiac remodelling were overexpressed ( Figure 6E) . Most impressive was .2-fold increase in mRNA for Ctgf (connective tissue growth factor), Tgfb1 (transforming growth factor beta 1), and Mmp8 and Mmp9 (matrix metalloproteinases-enzymes responsible for degradation of myocardial extracellular proteins). Levels of mRNA for Fgf12 (fibroblast growth factor 12) and Col1a2 (collagen type 1, alpha 2) were also elevated although to a lesser extent. Some increase was also seen in mRNA for Nppb (natriuretic peptide precursor B) . Overall, the results show a significant deterioration of cardiac performance after chronic treatment of mice with LNA-miR-448-3p inhibitor.
It should be mentioned that NOX2 is expressed in many tissues. Therefore, systemic inhibition of miR-448 can potentially increase NOX2 activity in tissues other than heart, including inflammatory cells where it is the most active. 4 A subsequent boost in inflammation could also, though indirectly, contribute to a deterioration of cardiac function in mice after LNA-miR-448 treatment. In addition, the release of pro-inflammatory cytokines can either prime or even increase NOX2 activation everywhere. Supplementary material online, Figure S3 illustrates the levels of selected cytokines in cardiac samples from control and LNA-miR-448-treated animals. It seems that acute inhibition of miR-448 did not induce dramatic changes in cytokines levels. Therefore, changes in intracellular Ca 2+ signalling and ROS production ( Figure 4 ) most likely were not influenced by the activation of inflammatory processes. Nevertheless, prolonged inhibition of miR-448 resulted in a robust increase in cytokines, which indeed may contribute to the development of fibrosis and the deterioration of cardiac function in treated mice ( Figures 5 and 6 ).
Discussion
The results of these studies reveal an important role of miR-448-3p in development of cardiac disease driven by oxidative stress. Animals systematically treated with LNA-miR-448-3p inhibitor exhibit significant decline of electrical and contractile properties of the heart. Cardiac dysfunctions were at least partially associated with deterioration of cardiac muscle tissue, in particular development of patches of fibrosis and morphological remodelling of cardiomyocytes. On the cellular level, inhibition of miR-448-3p results in significant increase in expression of the regulatory p47 phox subunit of NOX2 enzyme, enhanced NOX2-dependent ROS production, and amplified intracellular Ca 2+ signalling. The latter may in turn culminate in activation of Ca 2+ -dependent apoptotic and/or necrotic mechanisms, appearance of fibrotic patches and decrease in cardiac contractility, features that are often observed in pathological tissues, including dystrophic cardiac muscle. Our results extend recent reports of the role of miRs in cardiac disease and provide a novel insight into how expression of ROS-generating moieties, in particular NOX2, can be regulated at posttranscriptional level. To our knowledge these data provide the first evidence that systemic delivery of miR can directly control NOX2 expression in heart and impact cardiac functions. Because increased levels of NOX2 and/or its activity have been shown to be involved in several cardiac dysfunctions other than DMD (such as ROS-dependent hypertrophic cardiac responses, myocardial inflammation and fibrosis, post-MI remodelling as well as atrial fibrillation) our findings are important for a wide range of cardiac research.
miRs and cardiovascular disease
miRs are important regulator of gene expression. It is currently believed that they control, at least in part, many physiological and pathophysiological events in cardiovascular tissue. Dozens of miRs have already been identified to be involved in the regulation of cardiac muscle proliferation, regeneration and degeneration, development of cardiac arrhythmias, CH and HF. 18 -21,30 Multiple molecular targets of miRs have been identified. Some miRs directly regulate intracellular Ca 2+ handling/signalling and excitation -contraction coupling by targeting specific proteins involved in these processes. 30 Others, adjust the expression of various transcription factors and proteins during myocardial remodelling in cardiac disease. 18 Development of specific inhibitors and mimetics of miRs that can be locally or systemically delivered to the organisms, prompted an enthusiasm for miRs to become novel therapeutic targets. 21 The recent success in treatment of hepatitis C with antimiR treatment in a human clinical trial, as well as correction of cardiovascular problems in various animal models, made miR-based therapy very appealing. 
Specificity of targeting, tissue distribution, and biosynthesis of miR-448-3p
There are tens to hundreds of protein-coding genes regulated by a single miR. Because miRs identify certain 'seed sequences' in sections of genes, any gene containing a sequence complementary to the seed region is potentially regulated by the respective miR. Some of these genes can encode proteins involved in redox and Ca 2+ signalling pathways.
Therefore, we used several bioinformatics portals to predict alternative targets for miR-448-3p. Supplementary material online, Figure S4 shows that the expression of some potential target genes is changed in dystrophic hearts. Of specific interest is the Sri gene that encodes sorcin, a protein that is involved in the regulation of intracellular Ca 2+ signalling in cardiomyocytes. In particular, it has been demonstrated that sorcin reduces intracellular Ca 2+ responses by directly inhibiting RyR channels. 31, 32 Sri expression is slightly, but significantly, reduced in dystrophic hearts. This, in general, can result in partial removal of RyRs inhibition by sorcin and add to the enlarged Ca 2+ signalling observed in dystrophic cardiomyocytes. However, it is unlikely that sorcin is directly involved in regulation of the redox potential in young mdx hearts, as the contribution of Ca 2+ -dependent ROS-producing moieties, such as mitochondria, is limited at early stages of the disease. Among factors that influence the efficiency of miR targeting to a specific gene is tissue expression profile of miRs and the level of its expression. Tissue-specific or housekeeping miRs as well as highly expressed miRs usually have more robust effects on a target. Supplementary material online, Figure S5 illustrates the tissue expression profiles of miR-448-3p and its corresponding Htr2c gene. Htr2c is located at X chromosome and encodes serotonin receptor 2c. Thus, it was not a surprise to see that Htr2c expression was the highest in brain tissue. The Htr2c gene expression in heart was below the detection level (Supplementary material online, Figure S5A ). However, the significant level of miR-448-3p was detected in cardiac tissue and even in isolated cardiomyocytes (Supplementary material online, Figure S5B ). Therefore, although it is not a dominant miR in cardiac muscle, miR-448-3p is expressed there and is able to directly target cardiac NOX2 subunit.
It has long been believed that transcription of miR precursors depends on transcription of their host genes. However, recently published data suggest that at least one-third of intronic miRs has transcription initiation site that is independent from host gene promoter. 33, 34 Moreover, Gao et al. 35 has demonstrated that miR precursors can be 'self-transcribed', in the absence of exogenous promoters. Relevant to our studies, Zhang et al. 36 recently showed that the 5 ′ untranslated region (intron 2) mRNA of the Htr2c (intron 4 of Htr2c contains miR-448) is widely expressed in various non-neuronal cell lines, despite the fact that the mRNA of the protein-coding region of Htr2c was not detected in these cell lines. Several miRs, encoded in intron 2, were also expressed there. However, whereas intron 2 expression was similar in all cell lines studied, levels of miR were different, indicating cell-type-specific processing or stability of pre-miRs. In addition, Li et al. 37 found several predicted binding sites for transcription factors (such as NF-kB, AP1, c-Myc, and AP4) located within intron 4 of Htr2c gene upstream of pre-miR-448 stemloop sequence. They also showed that NF-kB (which expression is upregulated after systemic miR-448 inhibition, as shown in Figure 6D ) directly binds the promoter of miR-448, suppressing its transcription at least in some cell lines. Therefore, we can suggest that pre-miR448 transcription in the heart may be regulated independently of host Htr2c gene expression.
Overall, our findings reveal a pivotal role of miR-448-3p in development of NOX2-ROS-driven cardiomyopathy in mice. Although we are only just beginning to gain some insights into therapeutic application of miRs, it is clear that they are important players in the development of cardiovascular diseases. Our data suggest that miRs-regulating expression of NOX2 subunits could potentially become strategic therapeutic targets that would help to slow down deterioration of cardiac function not only in DMD patients but also in patients with other cardiac pathologies associated with oxidative stress.
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